M1 Allosteric Modulator Scaffold for Selective CNS Receptor Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for compounds with cholinergic muscarinic M1 receptor positive allosteric modulator activity to treat conditions such as Alzheimer's disease, schizophrenia, pain, sleep disorders, and Parkinson's disease dementia.
Innovation Solution
Development of a nitrogen-containing heterocyclic compound represented by formula (I) that acts as a cholinergic muscarinic M1 receptor positive allosteric modulator, enhancing receptor function by binding at a different site from the endogenous activator acetylcholine.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a compound is designed to bind at the orthosteric site of the M1 receptor like acetylcholine, then it can activate the receptor directly, but it cannot achieve the enhanced allosteric modulation effect required for therapeutic benefit
Solution Approach 1:
The invention introduces an allosteric modulator that binds at a distinct site from the orthosteric acetylcholine binding site on the M1 receptor. This intermediary compound (Formula I) acts as a mediator that enhances acetylcholine's effect without directly competing for the primary binding site, thereby achieving reliable therapeutic modulation through cooperative binding mechanisms
2Object-affected harmful factors
If the compound structure is highly specific to achieve selective M1 receptor binding, then it can reduce off-target effects, but it becomes more difficult to optimize for both potency and selectivity simultaneously
Solution Approach 1:
The compound of Formula I incorporates specific local structural features including a nitrogen-containing heterocyclic group (R1), specific substituent patterns (R2-R6), and a particular core structure (Ring A with specific substituents). These localized structural qualities provide selective interaction with M1 receptor residues while maintaining overall molecular flexibility for optimization
Solution Approach 2:
The invention systematically varies molecular parameters including the nitrogen-containing heterocyclic group type (R1), substituent identities (R2-R6), and ring A substitution patterns to optimize the balance between M1 receptor potency and selectivity. This parameter-based approach allows fine-tuning of binding characteristics without redesigning the entire molecular framework
3Loss of time
If existing compounds are used for M1 receptor modulation, then immediate therapeutic application is possible, but they lack the optimized profile for specific neurological conditions such as Alzheimer's disease
Solution Approach 1:
The invention performs preliminary optimization of the M1 modulator structure (Formula I) with specific attention to properties required for treating neurological conditions such as Alzheimer's disease, schizophrenia, and pain. The compound is pre-optimized for appropriate pharmacokinetic properties, blood-brain barrier penetration, and specific M1 selectivity before clinical application, reducing the time required for therapeutic deployment
Data Source
AI summary
The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.The present invention relates to a compound represented by the formula (I) or a salt thereof.wherein each symbol is as described in the specification, or a salt thereof.